Wolverine Trading, LLC Insmed Inc Call Options Transaction History

Wolverine Trading, LLC

16 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$22.0 - $69.71 $46,200 - $146,391	-2,100 Reduced 4.04%	49,900 $3.34 Million
Q1 2024 May 15, 2024	BUY	$25.72 - $29.94 $1.12 Million - $1.31 Million	43,700 Added 526.51%	52,000 $1.41 Million
Q4 2023 Feb 14, 2024	BUY	$23.42 - $31.74 $194,386 - $263,442	8,300 New	8,300 $257,000
Q2 2021 Aug 06, 2021	SELL	$24.17 - $36.01 $166,773 - $248,469	-6,900 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$32.28 - $44.3 $222,732 - $305,670	6,900 New	6,900 $223,000
Q2 2020 Aug 13, 2020	SELL	$14.11 - $29.42 $334,407 - $697,254	-23,700 Closed	0 $0
Q1 2020 May 11, 2020	SELL	$13.63 - $33.98 $213,991 - $533,486	-15,700 Reduced 39.85%	23,700 $406,000
Q4 2019 Feb 12, 2020	BUY	$16.12 - $24.98 $327,236 - $507,094	20,300 Added 106.28%	39,400 $923,000
Q3 2019 Nov 14, 2019	SELL	$15.49 - $25.78 $38,725 - $64,450	-2,500 Reduced 11.57%	19,100 $349,000
Q2 2019 Aug 20, 2019	BUY	$23.0 - $32.19 $59,800 - $83,694	2,600 Added 13.68%	21,600 $553,000
Q1 2019 May 15, 2019	BUY	$13.91 - $31.15 $264,290 - $591,850	19,000 New	19,000 $552,000
Q4 2018 Feb 14, 2019	SELL	$11.6 - $18.7 $451,240 - $727,430	-38,900 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$18.95 - $28.08 $361,945 - $536,328	19,100 Added 96.46%	38,900 $787,000
Q1 2018 May 15, 2018	SELL	$21.69 - $32.99 $15,183 - $23,093	-700 Reduced 3.41%	19,800 $446,000
Q4 2017 Feb 14, 2018	SELL	$26.43 - $31.78 $2.98 Million - $3.59 Million	-112,900 Reduced 84.63%	20,500 $639,000
Q3 2017 Nov 15, 2017	BUY	$11.61 - $31.21 $1.55 Million - $4.16 Million	133,400	133,400 $4.16 Million

447

170M

5.79M

5.18M

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $9.82B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.